

In the Claims:

A complete listing of claims 1-16 with status identifier follows.

Claims 1-14 (Cancelled)

Claim 15 (New) A method of treatment for non-inflammatory pain in a mammal comprising the administering of a KCNQ2/3 potassium channel opener to said mammal, wherein said KCNQ2/3 potassium channel opener is retigabine or linopirdine.

Claim 16 (New) A method for the treatment of muscle relaxation, fever reduction, anxiolytic, functional bowel disorder, tinnitus, ophthalmic disease or the prevention or reduction of tolerance to a dependence inducing agent comprising a KCNQ2/3 potassium channel opener selected from the group consisting of retigabine and linopirdine.